29 March 2025 in Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)
RPResearch and manufacturing company “Home оf Pharmacy
Research and manufacturing company “Home оf Pharmacy
B“Biotechnology Company Jsc “Biocad”
Biotechnology Company Jsc “Biocad”
SUSaint-Petersburg State Chemical and Pharmaceutical University
Saint-Petersburg State Chemical and Pharmaceutical University
IRInstitute of Experimental Medicine FGBU “Almazov NMMC” of the Ministry of Health of Russia
Institute of Experimental Medicine FGBU “Almazov NMMC” of the Ministry of Health of Russia
+18
This article reviews the historically established categories of laboratory animals — Specific pathogen free and Conventional — whose main difference in housing was considered to be the presence of barriers. In modern laboratories all animals are kept in barrier systems, regardless of their category, which may allow to unify the approach to quality assessment of laboratory animals used in biomedical research. Barriers can be diverse in design and fulfil different functions depending on their purpose. This article considers primary, secondary and hygienic barriers, the totality of which allows to maintain the health and well-being of laboratory animals. A set of requirements for each type of barrier ensures adequate protection and quality assurance of laboratory animals. Based on the reviewed barriers and their requirements, we propose to classify barriers into several levels: BC (barrier class) 1, 2, 3, 4 and 5. The proposed system can help research organisations to assess their own conditions for keeping laboratory animals and think about opportunities for improvement. In the future, this division of barriers in animal housing can provide an objective division of animal categories according to their health status and protection from pathogens.
2 March 2023 in Translational Medicine
Background. Research in oncology assumes establishment and usage of xenograft animal models, meeting the requirements of humanity and rationality. Although praised as promising field of research, preclinical studies of low-molecular-weight inhibitors, antitumor monoclonal antibodies, vaccines, cellular therapy products, CAR-T cells entail continuous control of tumor growth dynamics. Luciferase detection of bioluminescence requires injection of a reporter substrate. However, injections not only are laborious, time-consuming and expensive, but are also stressful for animals. Thus, a vast variety of new visualization methods is employed, including proteins of the far-red spectrum.Objective. The study aimed to compare detection efficiency of tumor growth dynamics in mice models of cervical cancer, applying a commercially available line of fluorescent red protein derivatives of Katushka clade and Renilla luciferase, that is commonly used in in vivo studies. Design and methods. Xenograft mice models were derived injecting modified HeLa cell line, that expresses fluorescent reporter proteins: Katushka, Katushka2S, TurboRFP, TurboFP650 and Renilla enzyme. Results. Spectral properties and emission wavelength of far-red fluorescent protein Katushka and Katushka2S outlines these markers within RFP derivatives lineage as outstanding instrument for in vivo tumor visualization.Conclusion. Detection of fluorescent far-red reporters Katushka and Katushka2S can be considered as a credible alternative to Renilla luciferase bioluminescence in experimental models in vivo on the part of immunotherapy research.
2 July 2025 in Regulatory Research and Medicine Evaluation
INTRODUCTION. The main risk to the clinical translatability of preclinical results for anticancer medicinal products is posed by the difficulty of simulating clinical conditions in an experimental model. With only 5% of product candidates proving clinically effective, the search for new approaches to the preclinical development of anticancer medicinal products is currently an active area of research in medicine.AIM. This study aimed to provide methodological support for planning experiments with modelling of neoplastic processes through analysis and classification of the methods used in preclinical studies of the efficacy of anticancer medicinal products in vivo.DISCUSSION. This article reviews the development of animal tumour models and the selection of cell lines and their testing for tumourigenicity and viability on a step-by-step basis. According to the study results, imaging systems, vital staining, and fluorescence- and luminescence-based methods can be used to assess the efficacy of anticancer medicinal products in both solid tumour models and haematological malignancy models. The article presents a schematic representation of the main types of mouse cancer models. However, no single animal species is universally suitable for in vivo cancer modelling. Researchers selecting models and considering their advantages and disadvantages should pay special attention to the similarity of disease mechanisms in animal models and humans at the tissue and molecular level, keeping in mind the aims of their research.CONCLUSIONS. The results of this comparative analysis of methods for preclinical efficacy evaluation of anticancer medicinal products are essential for designing experimental studies and ensuring the reliability of the results obtained. Choosing the correct research method will increase the chances of obtaining experimental data that can be successfully translated into clinical practice.
28 December 2025 in Journal of microbiology, epidemiology and immunobiology
КГКуляш Алексей Геннадьевич
Куляш Алексей Геннадьевич
+10
Introduction. The formation of biofilms by healthcare-associated infection (HAI) pathogens on invasive medical devices is an increasingly urgent problem in clinical practice. Microbial biofilms contribute to persistent infections, complicate treatment, increase healthcare costs, and reduce the quality of patient care. The resistance of biofilm-embedded bacteria to antibiotics is a key factor in chronic and recurrent infections. In this context, bacteriophages may serve as a promising therapeutic agent against bacterial infections, including those caused by biofilm-forming microorganisms. Objective. To assess the efficacy of lytic bacteriophages in disrupting microbial biofilms on urinary catheters using in vitro and in vivo experimental models. Materials and methods. The study employed microbiological, morphological, and electron microscopy techniques. In vitro, biofilms were cultured on urinary catheter surfaces and subsequently treated with bacteriophages. For the in vivo model, catheter-associated urinary tract infection (CAUTI) was induced in mice, which were then divided into experimental and control groups. Bacteriophages were administered transurethrally. Results. In the in vitro model, bacteriophages effectively disrupted biofilms, inducing bacterial cell lysis and degradation of the exopolysaccharide matrix. In the in vivo experiments, mice treated with bacteriophages exhibited regression of CAUTI, as confirmed by morphological and bacteriological analyses. Electron microscopy revealed biofilm destruction on 5 out of 6 catheters. In contrast, the positive control group showed progressive infection, while no biofilm formation was observed in the negative controls. Conclusions. The findings from both in vitro and in vivo experiments demonstrate that bacteriophages are capable of degrading biofilms and may represent an effective therapeutic strategy against biofilm-associated HAIs.